barclaysplc-batchfilingju
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August
01, 2023
Barclays PLC
(Name
of Registrant)
1 Churchill Place
London E14 5HP
England
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual
reports
under
cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
This
Report on Form 6-K is filed by Barclays PLC.
This
Report comprises:
Information
given to The London Stock Exchange and furnished pursuant
to
General
Instruction B to the General Instructions to Form 6-K.
EXHIBIT
INDEX
Exhibit
No. 1
|
Total
Voting Rights dated 03 July 2023
|
Exhibit
No. 2
|
Barclays
2022/23 BoE stress test results dated 12 July 2023
|
Exhibit
No. 3
|
Commencement
of Share Buyback Programme dated 28 July 2023
|
Exhibit
No. 4
|
Director/PDMR
Shareholding dated 28 July 2023
|
Exhibit
No. 5
|
Publication
of Suppl.Prospcts dated 28 July 2023
|
Exhibit
No. 6
|
Transaction
in Own Shares dated 31 July 2023
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BARCLAYS
PLC
|
|
(Registrant)
|
Date:
August 01, 2023
|
By: /s/
Garth Wright
--------------------------------
|
|
Garth
Wright
|
|
Assistant
Secretary
|
Exhibit
No. 1
3 July 2023
Barclays PLC
Total Voting Rights
In accordance with the Financial Conduct Authority's (FCA)
Disclosure Guidance and Transparency Rule 5.6.1R, Barclays PLC
notifies the market that as of 30 June 2023, Barclays PLC's issued
share capital consists of 15,555,768,747 Ordinary shares with
voting rights.
There are no Ordinary shares held in Treasury.
The above figure 15,555,768,747 may be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in,
Barclays PLC under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends
-
For further information, please contact:
Investor
Relations
Adam Strachan
+1 212 526 8442
|
James Johnson
+44 (0)20 7116 7233
|
Media
Relations
Jon Tracey
+44 (0)20 7116 4755
|
Exhibit
No. 2
12 July 2023
Barclays PLC
Barclays above all hurdle rates in 2022/23 Bank of England stress
test
Barclays PLC ("Barclays") notes the publication today of stress
test outcomes for UK banks by the Bank of England ("BoE"). Under
the BoE's assessment, Barclays continues to be sufficiently
capitalised by remaining above the respective hurdle rates for the
duration of the stress scenario. This is under both the common
equity tier 1 ratio and the tier 1 leverage ratio measures of
capital, and in terms of both transitional and non-transitional
bases for IFRS 9. This was also the case in the inaugural stress
test of Barclays Bank UK PLC, the ring-fenced bank.
The test demonstrates Barclays' continued robust and resilient
balance sheet position, and the capital target and plans remain as
before.
Barclays' group results from the BoE stress test are set out in the
table below.
Barclays PLC
|
Actual (June 2022)
|
Minimum stressed ratio (before strategic management
actions)
|
Minimum stressed ratio (after the impact of strategic management
actions)
|
Hurdle rate
|
Actual (March 2023)
|
IFRS9 Transitional
|
|
|
|
|
|
Common equity Tier 1 ratio(a)(b)
|
13.6%
|
8.0% (g)
|
8.5%
|
6.8%
|
13.6%
|
Tier 1 Capital ratio(c)
|
17.1%
|
11.2% (g)
|
11.8% (g)
|
|
17.6%
|
Total capital ratio(d)
|
19.9%
|
13.2% (g)
|
13.8% (g)
|
|
20.2%
|
Memo: risk-weighted assets (£ billions)
|
345
|
382 (g)
|
378 (g)
|
|
338
|
Memo: CET1 (£ billions)
|
47
|
30 (g)
|
32 (g)
|
|
46
|
Tier 1 leverage ratio(a)(e)
|
5.1%
|
3.5% (h)
|
3.7%
|
3.3%
|
5.1%
|
Memo: leverage exposure (£ billions)
|
1,151
|
1,132 (h)
|
1,108 (h)
|
|
1,169
|
IFRS9 non-transitional
|
|
|
|
|
|
Common equity Tier 1 ratio(f)
|
13.4%
|
6.9%
|
7.4%
|
6.7%
|
13.5%
|
Tier 1 leverage ratio(f)
|
5.1%
|
3.1%
|
3.4%
|
3.3%
|
5.1%
|
(a) The low points for the common equity Tier 1 (CET1) ratio and
leverage ratio shown in the table do not necessarily occur in the
same year of the stress scenario and correspond to the year where
the minimum stressed ratio is calculated after strategic management
actions. There is no conversion of banks' AT1 instruments in the
stress.
(b) The CET1 capital ratio is defined as CET1 capital expressed as
a percentage of the total risk exposure amount (risk-weighted
assets or RWAs), where CET1 capital and RWAs are determined in
accordance with the CRR.
(c) The Tier 1 capital ratio is defined as Tier 1 capital expressed
as a percentage of RWAs, where Tier 1 capital is defined as the sum
of CET1 capital and additional Tier 1 capital determined in
accordance with the CRR.
(d) The Total capital ratio is defined as total capital expressed
as a percentage of RWAs, where total capital is defined as the sum
of Tier 1 capital and Tier 2 capital determined in accordance with
the CRR.
(e) The Tier 1 leverage ratio is Tier 1 capital expressed as a
percentage of the leverage exposure measure, as defined in Article
429(2) of the Leverage Ratio (CRR) part of the PRA Rulebook. If a
firm does not have sufficient CET1 capital to meet 75% of the
leverage ratio minimum requirement and 100% of its leverage ratio
buffers (as required by PRA rules), additional Tier 1 capital has
been capped at 25% of the leverage ratio minimum requirement for
the purpose of calculating the Tier 1 leverage ratio.
(f) The low point year for the non-transitional IFRS 9 may differ
to the low point year on a transitional IFRS 9 basis.
(g) Corresponds to the same year as the minimum CET1 ratio over the
stress scenario after strategic management actions.
(h) Corresponds to the same year as the minimum leverage ratio over
the stress scenario after strategic management
actions.
- ENDS -
For further information, please contact:
Investor Relations
Media
Relations
Adam Strachan +1 212 526
8442
Jonathan Tracey +44 (0) 20 7116 4755
James Johnson +44 (0) 20 7116 7233
About Barclays
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and geography.
Our businesses include consumer banking and payments operations
around the world, as well as a top-tier, full service, global
corporate and investment bank, all of which are supported by our
service company which provides technology, operations and
functional services across the Group. For further information about
Barclays, please visit our website home.barclays
Forward-looking statements
This announcement contains forward-looking statements within the
meaning of Section 21E of the U.S. Securities Exchange Act of 1934,
as amended, and Section 27A of the U.S. Securities Act of 1933, as
amended, with respect to Barclays and the Barclays Group. Barclays
cautions readers that no forward-looking statement is a guarantee
of future performance and that actual results or other financial
condition or performance measures could differ materially from
those contained in the forward- looking statements. These
forward-looking statements can be identified by the fact that they
do not relate only to historical or current facts. Forward-looking
statements sometimes use words such as 'may', 'will', 'seek',
'continue', 'aim', 'anticipate', 'target', 'projected', 'expect',
'estimate', 'intend', 'plan', 'goal', 'believe', 'achieve' or other
words of similar meaning. These statements are based on the current
beliefs and expectations of Barclays' management and are subject to
significant risks and uncertainties. Actual outcomes may differ
materially from those expressed in the forward-looking statements.
Factors that could impact Barclays' future financial condition and
performance are identified in Barclays' filings with the SEC
(including, without limitation, Barclays' Annual Report on Form
20-F for the financial year ended 31 December 2022), which are
available on the SEC's website at www.sec.gov.
Subject to Barclays' obligations under the applicable laws and
regulations of any relevant jurisdiction, (including, without
limitation, the UK and the U.S.), in relation to disclosure and
ongoing information, we undertake no obligation to update publicly
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
No statement in this announcement is intended as a profit forecast
and no statement in this announcement should be interpreted to mean
that the earnings per share for the current or future years would
necessarily match or exceed the historical published earnings per
share.
Exhibit No. 3
28 July 2023
Barclays PLC
Commencement of Buy-back
Barclays PLC (the "Company") announces that, as outlined in its announcement
on 27 July 2023, it will commence a share buy-back programme to
purchase ordinary shares of 25 pence each in the Company
("Ordinary
Shares") for up to a maximum
consideration of £750m (the "Buy-back"). The Buy-back will commence on 28 July 2023 and
end no later than 27 January 2024 (subject to regulatory approval
remaining in place). The purpose of the Buy-back is to reduce the
share capital of the Company and therefore Ordinary Shares
purchased under the Buy-back will be cancelled.
The Company has entered into a non-discretionary agreement with
Citigroup Global Markets Limited ("Citi") to conduct the Buy-back on its behalf and carry
out on-market purchases of Ordinary Shares, acting as riskless
principal, and to on-sell such Ordinary Shares to the
Company.
Citi will make trading decisions in relation to the Buy-back
independently of, and without further instruction from, the
Company. Any purchases of Ordinary Shares under the Buy-back
will be carried out on the London Stock Exchange in accordance with
certain pre-set parameters set out in the agreement with Citi and
in accordance with (and subject to the limits prescribed by) the
Company's general authority to repurchase Ordinary Shares granted
by its shareholders at the annual general meeting on 3 May 2023
(the "2023
Authority"), Chapter 12 of the
Financial Conduct Authority's Listing Rules, Article 5(1) of the
Market Abuse Regulation (EU) No 596/2014 (as it forms part of
domestic law by virtue of the European Union (Withdrawal) Act 2018,
as amended), the Commission Delegated Regulation (EU) No 2016/1052
(as it forms part of domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended), and other applicable
laws.
No repurchases will be made in the United States or in respect of
the Company's American Depositary Receipts.
The maximum number of Ordinary Shares that may be repurchased under
the Buy-back is 1,587,136,913 being the number of Ordinary Shares
the Company is authorised to repurchase under the 2023
Authority.
- ENDS -
For further information, please contact:
Investor Relations
Media
Relations
Adam Strachan +1 212 526 8442
Jonathan Tracey +44 (0) 20 7116 4755
James Johnson +44 (0) 20 7116 7233
About Barclays
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and geography.
Our businesses include consumer banking and payments operations
around the world, as well as a top-tier, full service, global
corporate and investment bank, all of which are supported by our
service company which provides technology, operations and
functional services across the Group. For further information about
Barclays, please visit our website home.barclays.
Exhibit
No. 4
28 July 2023
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Taalib Shaah
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Group Chief Risk Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Barclays PLC
|
b)
|
LEI
|
213800LBQA1Y9L22JB70
|
4.1
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary shares with a nominal value of 25 pence each
("Shares")
GB0031348658
|
b)
|
Nature of the transaction
|
Disposal of Shares by Solium Capital UK Limited in its capacity as
administrator of the Barclays' nominee service.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s):
Number of Shares sold
|
£1.58 per Share
|
19,727
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable
|
e)
|
Date of the transaction
|
2023-07-27
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
For further information please contact:
Investor
Relations
|
Media
Relations
|
Adam Strachan
|
Jonathan Tracey
|
+1 212 526 8442
James Johnson
+44 (0)20 7116 7233
|
+44 (0)20 7116 4755
|
Exhibit
No. 5
Publication
of Base Prospectus Supplement
The
following base prospectus supplement ("Prospectus
Supplement") has been approved
by the Financial Conduct Authority and is available for
viewing:
Prospectus Supplement No. 2
dated 28 July 2023 to the Base Prospectus dated 7 March 2023 for
the Barclays PLC Debt Issuance Programme ("Base
Prospectus").
Please read
the disclaimer below "Disclaimer - Intended Addressees" before
attempting to access this service, as your right to do so is
conditional upon complying with the requirements set out
below.
To view the full document, please
paste the following URL into the address bar of your
browser.
http://www.rns-pdf.londonstockexchange.com/rns/6228H_1-2023-7-28.pdf
A copy of the above
document has been submitted to the National Storage Mechanism and
will shortly be available for inspection
at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further
information, please contact:
Barclays
Treasury
1 Churchill
Place
Canary
Wharf
London
E14 5HP
DISCLAIMER -
INTENDED ADDRESSEES
IMPORTANT: You must read the following
before continuing: The
following applies to the Prospectus Supplement available by
clicking on the link above, and you are therefore advised to read
this carefully before reading, accessing or making any other use of
the Prospectus Supplement. In accessing the Prospectus Supplement,
you agree to be bound by the following terms and conditions,
including any modifications to them, any time you receive any
information from us as a result of such
access.
THE
PROSPECTUS SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER
THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER
WHATSOEVER. THE PROSPECTUS SUPPLEMENT MAY ONLY BE DISTRIBUTED
OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS
DEFINED IN, AND IN RELIANCE ON, REGULATION S UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT") OR WITHIN THE UNITED
STATES TO QIBs (AS DEFINED BELOW) IN ACCORDANCE WITH RULE 144A
UNDER THE SECURITIES ACT ("RULE 144A"). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION
OF THE PROSPECTUS SUPPLEMENT IN WHOLE OR IN PART IS PROHIBITED.
FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A VIOLATION OF THE
SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER
JURISDICTIONS.
NOTHING IN THIS ELECTRONIC
PUBLICATION CONSTITUTES
AN OFFER
OF SECURITIES FOR SALE IN ANY JURISDICTION.
ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS
AND THE PROSPECTUS SUPPLEMENT HAVE NOT BEEN, AND WILL NOT BE,
REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES OR OTHER JURISDICTION. ANY NOTES ISSUED
OR TO BE ISSUED PURSUANT TO THE BASE PROSPECTUS AND THE PROSPECTUS
SUPPLEMENT MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH RULE 144A UNDER THE
SECURITIES ACT TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED
INSTITUTIONAL BUYERS (EACH A "QIB") WITHIN THE MEANING OF RULE 144A OR (2) IN AN
OFFSHORE TRANSACTION TO A PERSON THAT IS NOT A U.S. PERSON IN
ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE
SECURITIES ACT.
Please note that the information
contained in the Base Prospectus and the Prospectus Supplement may
be addressed to and/or targeted at persons who are residents of
particular countries (specified in the Base Prospectus) only and is
not intended for use and should not be relied upon by any person
outside these countries and/or to whom the offer contained in the
Base Prospectus is not addressed. Prior to relying on the
information contained in the Base Prospectus and the Prospectus
Supplement you must ascertain from the Base Prospectus whether or
not you are part of the intended addressees of the information
contained therein.
Confirmation
of your Representation: In order to be eligible to view the
Prospectus Supplement or make an investment decision with respect
to any Notes issued or to be issued pursuant to the Base Prospectus
and the Prospectus Supplement, you must be (i) a person other than
a U.S. person (within the meaning of Regulation S under the
Securities Act); or (ii) a QIB that is acquiring the securities for
its own account or for the account of another QIB. By accessing the
Prospectus Supplement, you shall be deemed to have represented that
you and any customers you represent are not U.S. persons (as
defined in Regulation S to the Securities Act) or that you are a
QIB, and that you consent to delivery of the Prospectus Supplement
and any supplements thereto via electronic
publication.
You are
reminded that the Prospectus Supplement has been made available to
you on the basis that you are a person into whose possession the
Prospectus Supplement may be lawfully delivered in accordance with
the laws of the jurisdiction in which you are located and you may
not, nor are you authorised to, deliver the Prospectus Supplement
to any other person.
The Prospectus Supplement does not
constitute, and may not be used in connection with, an offer or
solicitation in any place where offers or solicitations are not
permitted by law. If a jurisdiction requires that the offering be
made by a licensed broker or dealer and the underwriters or any
affiliate of the underwriters is a licensed broker or dealer in
that jurisdiction, the offering shall be deemed to be made by the
underwriters or such affiliate on behalf of the issuer in such
jurisdiction. Under no circumstances shall the Prospectus
Supplement constitute an offer to sell, or the solicitation of an
offer to buy, nor shall there be any sale of any Notes issued or to
be issued pursuant to the Base Prospectus and the Prospectus
Supplement, in any jurisdiction in which such offer, solicitation
or sale would be unlawful.
The Prospectus Supplement has been
made available to you in an electronic form. You are reminded that
documents transmitted via this medium may be altered or changed
during the process of electronic transmission and consequently none
of the issuer, its advisers nor any person who controls any of them
nor any director, officer, employee nor agent of it or affiliate of
any such person accepts any liability or responsibility whatsoever
in respect of any difference between the Prospectus Supplement made
available to you in electronic format and the hard copy version
available to you on request from the issuer.
Your right to access this service is
conditional upon complying with the above
requirement.
Exhibit
No. 6
31 July 2023
Barclays PLC
Transaction in own shares
Barclays PLC (the "Company") announces that it has purchased for
cancellation the following number of its ordinary shares of 25
pence each on the London Stock Exchange from Citigroup Global
Markets Limited as part of its buy-back announced on 28 July
2023:
Date
of purchase:
|
28
July 2023
|
Number
of ordinary shares purchased:
|
6,951,810
|
Highest
price paid per share:
|
156.2000p
|
Lowest
price paid per share:
|
154.2400p
|
Volume
weighted average price paid per share:
|
155.3951p
|
The Company intends to cancel all of the purchased ordinary
shares.
Following the cancellation of the repurchased shares, the Company's
issued share capital will consist of 15,551,450,920 ordinary shares
with voting rights.
There are no ordinary shares held in Treasury.
The above figure (15,551,450,920) may be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
In accordance with Article 5(1)(b) of the Market Abuse Regulation
(EU) No 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended, a full breakdown
of the individual purchases of ordinary shares made by Citigroup
Global Markets Limited on behalf of the Company can be found
at:
http://www.rns-pdf.londonstockexchange.com/rns/6352H_1-2023-7-28.pdf
- ENDS -
For further information, please contact:
Investor Relations
Media
Relations
Adam Strachan +1 212 526 8442
Jonathan Tracey +44 (0)
20 7116 4755
James Johnson +44 (0) 20 7116 7233